The Role of Medical Management for Acute Intravascular Hemolysis in Patients Supported on Axial Flow LVAD

Tal Hasin, Salil Deo, Joseph Maleszewski, Yan Topilsky, Brooks Sayre Edwards, Naveen Luke Pereira, John M. Stulak, Lyle Joyce, Richard Daly, Sudhir S. Kushwaha, Soon J. Park

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Continuous flow left ventricular assist devices (LVADs) are used with good outcome. However, acute intravascular hemolysis due to thrombus in the pump remains a clinical challenge. We screened for LVAD-related intravascular hemolysis among 115 consecutive patients surviving HeartMateII implantation and investigated the role of medical therapy in resolving the hemolysis. Hemolytic events were identified in 7% of patients, 2-26 months after implant, manifested by peak lactate dehydrogenase (LDH) levels >6 times normal. With the institution of heparin and enhanced antiplatelet therapy, LDH levels receded rapidly reaching a stable trough level near baseline within 2 weeks with the resolution of clinical symptoms except in one patient who required additional therapy with tissue plasminogen activator (tPA). Complications included transient renal failure, one splenic infarct, and a cerebrovascular attack after tPA. The acute event of hemolysis resolved with medical therapy, and all were successfully discharged. However, recurrent hemolysis was common (6/8 patients over the next 1-7 months). At the end of follow-up, three patients were transplanted, one patient died refusing LVAD exchange for recurrent hemolysis, and 4 remained alive on LVAD support. Medical treatment with intensification of anticoagulation can be effective in resolving the acute hemolytic event. However, a definitive long-term strategy should be planned because the recurrence rate is high.

Original languageEnglish (US)
Pages (from-to)9-14
Number of pages6
JournalASAIO Journal
Volume60
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Left ventricular assist devices
Heart-Assist Devices
Axial flow
Hemolysis
Tissue Plasminogen Activator
L-Lactate Dehydrogenase
Tissue
Splenic Infarction
Therapeutics
Heparin
Pumps
Renal Insufficiency
Thrombosis
Recurrence
Oxidoreductases

Keywords

  • Heart assist device
  • hemolysis
  • management
  • outcome
  • thrombosis

ASJC Scopus subject areas

  • Biophysics
  • Biomaterials
  • Bioengineering
  • Biomedical Engineering
  • Medicine(all)

Cite this

The Role of Medical Management for Acute Intravascular Hemolysis in Patients Supported on Axial Flow LVAD. / Hasin, Tal; Deo, Salil; Maleszewski, Joseph; Topilsky, Yan; Edwards, Brooks Sayre; Pereira, Naveen Luke; Stulak, John M.; Joyce, Lyle; Daly, Richard; Kushwaha, Sudhir S.; Park, Soon J.

In: ASAIO Journal, Vol. 60, No. 1, 2014, p. 9-14.

Research output: Contribution to journalArticle

Hasin, Tal ; Deo, Salil ; Maleszewski, Joseph ; Topilsky, Yan ; Edwards, Brooks Sayre ; Pereira, Naveen Luke ; Stulak, John M. ; Joyce, Lyle ; Daly, Richard ; Kushwaha, Sudhir S. ; Park, Soon J. / The Role of Medical Management for Acute Intravascular Hemolysis in Patients Supported on Axial Flow LVAD. In: ASAIO Journal. 2014 ; Vol. 60, No. 1. pp. 9-14.
@article{14c5705e89af49c2bc01e9620b90dd03,
title = "The Role of Medical Management for Acute Intravascular Hemolysis in Patients Supported on Axial Flow LVAD",
abstract = "Continuous flow left ventricular assist devices (LVADs) are used with good outcome. However, acute intravascular hemolysis due to thrombus in the pump remains a clinical challenge. We screened for LVAD-related intravascular hemolysis among 115 consecutive patients surviving HeartMateII implantation and investigated the role of medical therapy in resolving the hemolysis. Hemolytic events were identified in 7{\%} of patients, 2-26 months after implant, manifested by peak lactate dehydrogenase (LDH) levels >6 times normal. With the institution of heparin and enhanced antiplatelet therapy, LDH levels receded rapidly reaching a stable trough level near baseline within 2 weeks with the resolution of clinical symptoms except in one patient who required additional therapy with tissue plasminogen activator (tPA). Complications included transient renal failure, one splenic infarct, and a cerebrovascular attack after tPA. The acute event of hemolysis resolved with medical therapy, and all were successfully discharged. However, recurrent hemolysis was common (6/8 patients over the next 1-7 months). At the end of follow-up, three patients were transplanted, one patient died refusing LVAD exchange for recurrent hemolysis, and 4 remained alive on LVAD support. Medical treatment with intensification of anticoagulation can be effective in resolving the acute hemolytic event. However, a definitive long-term strategy should be planned because the recurrence rate is high.",
keywords = "Heart assist device, hemolysis, management, outcome, thrombosis",
author = "Tal Hasin and Salil Deo and Joseph Maleszewski and Yan Topilsky and Edwards, {Brooks Sayre} and Pereira, {Naveen Luke} and Stulak, {John M.} and Lyle Joyce and Richard Daly and Kushwaha, {Sudhir S.} and Park, {Soon J.}",
year = "2014",
doi = "10.1097/MAT.0000000000000012",
language = "English (US)",
volume = "60",
pages = "9--14",
journal = "ASAIO Journal",
issn = "0162-1432",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The Role of Medical Management for Acute Intravascular Hemolysis in Patients Supported on Axial Flow LVAD

AU - Hasin, Tal

AU - Deo, Salil

AU - Maleszewski, Joseph

AU - Topilsky, Yan

AU - Edwards, Brooks Sayre

AU - Pereira, Naveen Luke

AU - Stulak, John M.

AU - Joyce, Lyle

AU - Daly, Richard

AU - Kushwaha, Sudhir S.

AU - Park, Soon J.

PY - 2014

Y1 - 2014

N2 - Continuous flow left ventricular assist devices (LVADs) are used with good outcome. However, acute intravascular hemolysis due to thrombus in the pump remains a clinical challenge. We screened for LVAD-related intravascular hemolysis among 115 consecutive patients surviving HeartMateII implantation and investigated the role of medical therapy in resolving the hemolysis. Hemolytic events were identified in 7% of patients, 2-26 months after implant, manifested by peak lactate dehydrogenase (LDH) levels >6 times normal. With the institution of heparin and enhanced antiplatelet therapy, LDH levels receded rapidly reaching a stable trough level near baseline within 2 weeks with the resolution of clinical symptoms except in one patient who required additional therapy with tissue plasminogen activator (tPA). Complications included transient renal failure, one splenic infarct, and a cerebrovascular attack after tPA. The acute event of hemolysis resolved with medical therapy, and all were successfully discharged. However, recurrent hemolysis was common (6/8 patients over the next 1-7 months). At the end of follow-up, three patients were transplanted, one patient died refusing LVAD exchange for recurrent hemolysis, and 4 remained alive on LVAD support. Medical treatment with intensification of anticoagulation can be effective in resolving the acute hemolytic event. However, a definitive long-term strategy should be planned because the recurrence rate is high.

AB - Continuous flow left ventricular assist devices (LVADs) are used with good outcome. However, acute intravascular hemolysis due to thrombus in the pump remains a clinical challenge. We screened for LVAD-related intravascular hemolysis among 115 consecutive patients surviving HeartMateII implantation and investigated the role of medical therapy in resolving the hemolysis. Hemolytic events were identified in 7% of patients, 2-26 months after implant, manifested by peak lactate dehydrogenase (LDH) levels >6 times normal. With the institution of heparin and enhanced antiplatelet therapy, LDH levels receded rapidly reaching a stable trough level near baseline within 2 weeks with the resolution of clinical symptoms except in one patient who required additional therapy with tissue plasminogen activator (tPA). Complications included transient renal failure, one splenic infarct, and a cerebrovascular attack after tPA. The acute event of hemolysis resolved with medical therapy, and all were successfully discharged. However, recurrent hemolysis was common (6/8 patients over the next 1-7 months). At the end of follow-up, three patients were transplanted, one patient died refusing LVAD exchange for recurrent hemolysis, and 4 remained alive on LVAD support. Medical treatment with intensification of anticoagulation can be effective in resolving the acute hemolytic event. However, a definitive long-term strategy should be planned because the recurrence rate is high.

KW - Heart assist device

KW - hemolysis

KW - management

KW - outcome

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84891873763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891873763&partnerID=8YFLogxK

U2 - 10.1097/MAT.0000000000000012

DO - 10.1097/MAT.0000000000000012

M3 - Article

C2 - 24322715

AN - SCOPUS:84891873763

VL - 60

SP - 9

EP - 14

JO - ASAIO Journal

JF - ASAIO Journal

SN - 0162-1432

IS - 1

ER -